What is the CT severity score for COVID-19 and how is it interpreted?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

CT Severity Score in COVID-19

The CT severity score (CT-SS) is a semi-quantitative scoring system that divides each lung into 20 regions, assigning each region a score of 0 (no involvement), 1 (<50% involvement), or 2 (≥50% involvement), yielding a total possible score of 0-40 points. 1

How the Score is Calculated

The scoring system evaluates lung parenchymal opacification across 20 anatomical segments:

  • Each of the 5 lobes is divided into 4 regions
  • Score 0: No parenchymal involvement
  • Score 1: Less than 50% of the region shows ground-glass opacities or consolidation
  • Score 2: 50% or more of the region is involved
  • Total score ranges from 0 to 40 1, 2

Clinical Interpretation and Severity Thresholds

A CT severity score of ≥19.5 is the validated threshold for identifying severe COVID-19 disease, with 83-84% sensitivity and 92-94% specificity 1, 3, 2. This cutoff effectively discriminates between mild and severe clinical presentations.

Alternative Scoring Systems

While multiple CT scoring systems exist (ranging from CT-SS 5 to CT-SS 30), the CT-SS 30 system demonstrated the highest diagnostic accuracy (AUC = 0.805) in a 2024 validation study 4. However, the traditional 0-40 point system remains most widely used and validated across multiple studies.

Correlation with Clinical Parameters

The CT severity score shows moderate to strong correlations with key clinical and laboratory markers:

  • Strongest correlation: LDH (ρ = 0.68) 5
  • Negative correlations: SpO2, lymphocyte percentage, serum albumin 5, 6
  • Positive correlations: CRP, ferritin, fibrinogen, D-dimer, neutrophil percentage 5, 6

In multivariable analysis, LDH, glucose, creatinine, and lymphocyte percentage independently predict CT severity score, explaining approximately 40% of its variance 5.

Anatomical Distribution Patterns

The lower lobes are most frequently and severely involved, particularly:

  • Posterior basal segments (left: 81/102; right: 83/102 cases)
  • Superior segments of lower lobes
  • Lateral basal segments 1, 3

The posterior segments of upper lobes are also commonly affected, but lower lobe involvement shows the strongest correlation with disease severity 1, 5.

Clinical Application Context

When CT Scoring is Appropriate

Based on Fleischner Society guidelines 7, 8:

  • Indicated: Patients with moderate-severe clinical features and worsening respiratory status
  • Indicated: Resource-constrained settings for medical triage when RT-PCR unavailable or negative
  • NOT indicated: Mild cases without risk factors for progression
  • NOT indicated: Routine screening in asymptomatic individuals

Prognostic Value

Each 1-point increase in CT severity score is associated with a 1.048-fold increase in mortality risk 9. A score of ≥25.5 predicts mortality with 75% sensitivity and 85.7% specificity (AUC = 0.857) 9.

Important Caveats

  • Predominance of consolidations or mixed consolidation/ground-glass opacities predicts more severe disease, while ground-glass opacities alone do not 4
  • CT findings are nonspecific and must be interpreted within clinical context
  • Daily chest radiographs are NOT indicated in stable intubated COVID-19 patients 7, 8
  • Interobserver agreement for CT severity scoring is excellent (ICC: 0.982-0.995) 4, making it reproducible across radiologists

References

Research

CT Chest Severity Score for COVID 19 Pneumonia: A Quantitative Imaging Tool for Severity Assessment of Disease.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2021

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.